China National Pharmaceutical Group (Sinopharm) said on Thursday that it has inoculated nearly a million people with its vaccine in the country.
"Our vaccines have been given to about one million people and we have not received any information about serious negative reactions", said Sinopharm's Chairman, Liu Jingzhen.
Volunteers from a variety of age groups and backgrounds, including some of the thousands who have registered to be contacted about vaccine studies through the NHS COVID-19 Vaccine Research Registry, have begun taking part in the latest study at 17 National Institute for Health Research (NIHR) sites across the United Kingdom, including MFT.
Adar Poonawaala, the chief executive of the SII, said that his company would seek emergency use authorisation for the AstraZeneca vaccine as soon as authorities in the United Kingdom approved it and made it available for the general public.
The terms of references for two major bodies dealing with vaccine introduction - the National Technical Advisory Group on Immunisation (NTAGI) and the Central Drug Standards and Control Organisation (CDSCO) - will be set and their roles clearly defined for authorisation and emergency authorisation. However, no adverse reactions have been reported by the state, the company or the trial participants, said Sinopharm.
According to details, the vaccine that is undergoing the third phase of a clinical trial in Pakistan has shown positive results with 95 percent recovery rate of the patients who were about to be shifted on a ventilator.
An indigenously developed vaccine by Zydus Cadila has completed phase-two clinical trial in the country. 40,000 participants have had blood samples taken upon being administered the second dose, said Jingzhen. At the same time, the National Expert Group on Vaccine Administration for Kovid-19 should play a leading role in deciding the principles for advance market commitments, including the value of vaccines.